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Patrick F. Sullivan1,2,3Editorial summary
Copy number variation (CNV) is a widely replicated
risk factor for psychiatric disorders such as schizophre-
nia, although the mechanisms by which CNVs confer
risk are currently unclear. Recent studies have provided
robust evidence of CNVs associated with schizophrenia
and have highlighted a potential role for schizophrenia
risk-associated CNVs in impairing inhibitory learning;
these studies highlight how insights can be gained into
the associations of CNVs with schizophrenia.Copy number variation and the human genome
The human genome is not static, and changes of many
types and at many scales occur in the creation of every
generation. One of the more interesting types of genetic
alteration is copy number variation (CNV). Germline
CNVs occur with some regularity, and certain genomic
regions are more prone to developing CNVs than others
owing to an increased chance of errors occurring at
certain locations during meiosis [1]. Most CNVs are
small and have no impact, but larger CNVs can change
the number of copies of one or more genes from the
normal inherited complement.
The impact of a CNV depends on the gene, as some
genes can be duplicated or deleted with no observable ef-
fect. Some CNVs can even provide benefit or protection
against environmental exposures [2]. However, the func-
tion of some genes is exquisitely sensitive to dosage. A
CNV that leads to an increase or a decrease from the nor-
mal inherited complement of a gene that is important to
the development or function of the central nervous system
can markedly increase the risk of an individual developing
a psychiatric disorder such as schizophrenia or autism [3].
Two recent reports [4, 5] have markedly augmented
our knowledge of schizophrenia and, as with all worthy
papers, they answer some questions and raise intriguing
new ideas.Correspondence: pfsulliv@med.unc.edu
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The first unequivocal genetic risk factor for schizophre-
nia was a CNV. In the 1990s, several groups described a
strong association of a one-copy loss of a three million
base pair region on chromosome 22 [6]. This deletion of
22q11 leads to a multisystem disorder known as velocar-
diofacial syndrome or 22q11 deletion syndrome, and
individuals with this disorder have an increased risk of
developing multiple conditions including schizophrenia.
The basic association has replicated well [4], and the de-
leted region contains more than 50 genes, many of which
are expressed in brain. This discovery has led to large-
scale searches for CNVs associated with schizophrenia.
Multiple studies have been undertaken, but a major issue
is that the genomic signals being searched for can be sub-
tle, variable, and difficult to replicate. Quality control for
CNV studies is also notoriously complex, and it can be ex-
tremely challenging to identify robust findings.
The pinnacle of CNV searches for schizophrenia to
date is a study from the CNV Working Group of the
Psychiatric Genomics Consortium, which was led by
Jonathan Sebat [4]. Although I am a co-author on this
paper, this work is arguably the most careful and com-
prehensive study of CNVs that has so far been con-
ducted in human genomics. The reason for this is that
the authors took exceptional care in processing the data.
Beginning with intensity files for 21,094 schizophrenia
cases and 20,227 controls, they applied multiple CNV
calling programs with careful quality control. This was a
massive effort, and the study took a team of scientists
more than 4 years to complete.
The authors reported that people with schizophrenia
carry a mean of 11% more CNVs than do controls, and
schizophrenia-associated CNVs particularly affected
genes involved in synaptic function. They found strong
evidence that eight CNVs were associated with schizo-
phrenia and noted suggestive support for eight more.
Most of these CNVs had already been reported, but the
authors presented evidence that there are more CNVs
to be discovered. The CNVs discovered to date are the
‘low-hanging fruit’ and have been relatively easy to
detect owing to their large sizes, their relatively high
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may be missing smaller or more complicated CNVs, the
identification of which will require whole-genome sequen-
cing. Larger studies, which are being planned by Sebat
and colleagues, could also identify more CNVs.
CNVs and the pathophysiology of schizophrenia
A crucial and as yet unanswered question is how each
of these CNVs connects to the pathophysiology of
schizophrenia. CNVs that affect the neurexin 1 gene
(NRXN1) increase the risk of an individual developing
schizophrenia [7], and neurexin 1 is critical to the
formation and function of synapses [8]. Sekar et al. [9]
studied a copy number polymorphism in the gene en-
coding complement component 4 (C4). They found
that C4 alleles tracked with risk of schizophrenia and
showed that C4 mediated synapse elimination in a par-
tially relevant mouse developmental model. The find-
ings implicate complement activity in synaptic pruning
(that is, the streamlining of synaptic connections) in
schizophrenia.
CNVs that affect single genes such as NRXN1 and C4
are somewhat more tractable than are large CNVs,
which may contain dozens of genes. The study by Clif-
ton et al. [5] applied a clever alternative strategy to ad-
dress this issue by exploring the molecular neurobiology
of associative learning. Abnormalities in associative
learning have been associated with schizophrenia, and
the authors investigated whether the presence of
schizophrenia-associated CNVs might be connected with
specific phases of associative learning. Using a rat model,
the authors looked for changes in gene expression
during consolidation, retrieval, or extinction (that is, a
decline in the conditioned response) of associative mem-
ories such as fear. After statistically assessing gene
expression in the rats, they identified differentially
expressed genes and their homologous human counter-
parts. The authors asked whether the genes connected
with these memory-related processes were also found in
CNVs that were more common in patients with schizo-
phrenia than in healthy controls. The authors assumed
that the rat and human genes had similar functions;
although there certainly are differences between rats and
humans that have arisen in the approximately 65 million
years since the last common ancestor, many neurobio-
logical processes are highly conserved. The authors’ ana-
lyses implicated genes involved in fear extinction, but
not those involved in consolidation or retrieval. The re-
sults of this study suggest that CNVs impair inhibitory
learning and may contribute to the development of some
of the psychotic symptoms of schizophrenia.
This is a fascinating result as it suggests that rodent
gene expression studies that use careful behavioral para-
digms (which could never be carried out with humans)can propose directed hypotheses for future experiments.
It also suggests that fear may be a crucial part of
schizophrenia.
We certainly know that patients with psychosis are
often intensely afraid owing to the content of their
hallucinations or delusions (for example, a persecutory
delusion that one is being incessantly and maliciously
observed). Fear can also be a common factor in the
experience of stressful life events. The authors raise the
intriguing possibility that the powerful emotion of fear
and the way in which fear is processed may be more
fundamental to schizophrenia than we currently think.
As with all good studies, addressing some hypotheses
raised more new questions. The application of single-
cell RNA sequencing has proven to be exceptionally in-
formative in neuroscience, and it would be intriguing to
see its application here. It might also be interesting to
investigate whether persistent, unpredictable stress
(which may induce fear) during pubescence leads to
lasting changes in adulthood.
These two intriguing studies [4, 5] suggest a larger
lesson: that we are entering a golden age of schizophre-
nia research. Many research groups are working on
CNVs that predispose to schizophrenia with approaches
ranging from functional genomics to molecular neuro-
science to evaluating patient-derived neuronal models.
CNVs are complex, but these recent studies have
highlighted how insights can be gained into their asso-
ciations with schizophrenia risk. One can hope that
progressive increases in knowledge will become the
norm for this debilitating psychiatric disorder.
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